Status:
COMPLETED
Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Atherosclerotic Cardiovascular Disease (ASCVD)
Benign Prostatic Hypertrophy (BPH)
Eligibility:
MALE
45+ years
Brief Summary
To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).
Eligibility Criteria
Inclusion
- patients diagnosed with BPH or users of 5-ARIs
Exclusion
- individuals who had cancer prior to the start of follow-up and those with pre-existing ASCVD
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT07196280
Start Date
January 1 2012
End Date
December 31 2022
Last Update
September 29 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.